{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:13:51Z","timestamp":1793279631143,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA023074"],"award-info":[{"award-number":["CA023074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01CA229418"],"award-info":[{"award-number":["1R01CA229418"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ES006694"],"award-info":[{"award-number":["ES006694"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ES007091"],"award-info":[{"award-number":["ES007091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012728","name":"Frederick National Laboratory for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jid.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T13:18:12Z","timestamp":1634822292000},"page":"1456-1465.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor\u2012Resistant BRAFV600E\/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9100-9574","authenticated-orcid":false,"given":"Jana","family":"Jandova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4799-8608","authenticated-orcid":false,"given":"Georg T.","family":"Wondrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.10.007_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","article-title":"Phenotype plasticity as enabler of melanoma progression and therapy resistance","volume":"19","author":"Arozarena","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jid.2021.10.007_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CMR.0b013e3283364903","article-title":"GLO1 overexpression in human malignant melanoma","volume":"20","author":"Bair","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jid.2021.10.007_bib3","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.10.007_bib4","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3892\/ijo.2016.3594","article-title":"Targeting the PI3K\/AKT\/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor","volume":"49","author":"Caporali","year":"2016","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jid.2021.10.007_bib5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PAI.0000000000000071","article-title":"BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma","volume":"23","author":"Chiappetta","year":"2015","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jid.2021.10.007_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/pcmr.12666","article-title":"Transcription factors as critical players in melanoma invasiveness, drug resistance, and opportunities for therapeutic drug development","volume":"31","author":"Cohen-Solal","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2021.10.007_bib7","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.10.007_bib8","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated molecular and clinical analysis of AKT activation in metastatic melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2021.10.007_bib9","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1074\/jbc.M114.592626","article-title":"The quinone methide aurin is a heat shock response inducer that causes proteotoxic stress and Noxa-dependent apoptosis in malignant melanoma cells","volume":"290","author":"Davis","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2021.10.007_bib10","series-title":"Medical genetics summaries","article-title":"Vemurafenib therapy and BRAF and NRAS genotype","author":"Dean","year":"2017"},{"key":"10.1016\/j.jid.2021.10.007_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (Columbus): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jid.2021.10.007_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ijc.23876","article-title":"Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in\u00a0vitro","volume":"124","author":"Eskandarpour","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2021.10.007_bib13","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: biological behavior and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2021.10.007_bib14","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","article-title":"Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma","volume":"10","author":"Gibney","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jid.2021.10.007_bib15","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/jid.2011.239","article-title":"SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I\/alpha2beta1 integrin axis","volume":"131","author":"Girotti","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.10.007_bib16","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.jid.2016.06.011","article-title":"NRAS, which mutation is fairest of them all?","volume":"136","author":"Grill","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.10.007_bib17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.21873\/cgp.20152","article-title":"The FOXC2 transcription factor promotes melanoma outgrowth and regulates expression of genes associated with drug resistance and interferon responsiveness","volume":"16","author":"Hargadon","year":"2019","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1016\/j.jid.2021.10.007_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/cells9010142","article-title":"Dissecting mechanisms of melanoma resistance to BRAF and MEK inhibitors revealed genetic and non-genetic patient- and drug-specific alterations and remarkable phenotypic plasticity","volume":"9","author":"Hartman","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jid.2021.10.007_bib19","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-017-3529-5","article-title":"Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care","volume":"17","author":"Heppt","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jid.2021.10.007_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3390\/cancers13040605","article-title":"Deuterium oxide (D2O) induces early stress response gene expression and impairs growth and metastasis of experimental malignant melanoma","volume":"13","author":"Jandova","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.10.007_bib21","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3390\/cancers12061369","article-title":"Genetic target modulation employing CRISPR\/Cas9 identifies glyoxalase 1 as a novel molecular determinant of invasion and metastasis in A375 human malignant\u00a0melanoma cells in\u00a0vitro and in\u00a0vivo","volume":"12","author":"Jandova","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.10.007_bib22","doi-asserted-by":"crossref","first-page":"102042","DOI":"10.1016\/j.redox.2021.102042","article-title":"Topical hypochlorous acid (HOCl) blocks inflammatory gene expression and tumorigenic progression in UV-exposed SKH-1 high risk mouse skin","volume":"45","author":"Jandova","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.jid.2021.10.007_bib23","doi-asserted-by":"crossref","first-page":"101838","DOI":"10.1016\/j.redox.2020.101838","article-title":"Genomic GLO1 deletion modulates TXNIP expression, glucose metabolism, and redox homeostasis while accelerating human A375 malignant melanoma tumor growth","volume":"39","author":"Jandova","year":"2021","journal-title":"Redox Biol"},{"key":"10.1016\/j.jid.2021.10.007_bib24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","article-title":"Treatment of advanced melanoma in 2020 and beyond","volume":"141","author":"Jenkins","year":"2021","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.10.007_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/mmt.15.40","article-title":"NRAS mutant melanoma: an overview for the clinician for melanoma management","volume":"3","author":"Jenkins","year":"2016","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.jid.2021.10.007_bib26","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2021.10.007_bib27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/onc.2010.408","article-title":"Hyperactivation of MEK-ERK1\/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells","volume":"30","author":"Kaplan","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2021.10.007_bib28","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1038\/s41388-018-0632-2","article-title":"Growth suppression by dual BRAF(V600E) and NRAS(Q61) oncogene expression is mediated by SPRY4 in melanoma","volume":"38","author":"Kumar","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2021.10.007_bib29","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.10.007_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fonc.2015.00031","article-title":"Phenotype switching in melanoma: implications for progression and therapy","volume":"5","author":"Li","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2021.10.007_bib31","doi-asserted-by":"crossref","first-page":"27714","DOI":"10.1074\/jbc.M113.532432","article-title":"Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells","volume":"289","author":"Lidsky","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jid.2021.10.007_bib32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2019.00268","article-title":"Diverse mechanisms of BRAF inhibitor resistance in melanoma identified in clinical and preclinical studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jid.2021.10.007_bib33","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1158\/1078-0432.CCR-19-2773","article-title":"Targeting\u00a0extracellular matrix remodeling restores BRAF inhibitor sensitivity in BRAFi-resistant melanoma","volume":"26","author":"Marusak","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jid.2021.10.007_bib34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/pcmr.12132","article-title":"Paradoxical oncogenesis: are all BRAF inhibitors equal?","volume":"26","author":"Menzies","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jid.2021.10.007_bib35","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.3390\/ijms20184484","article-title":"Long-term vemurafenib exposure induced alterations of cell phenotypes in melanoma: increased cell migration and its association with EGFR expression","volume":"20","author":"Moln\u00e1r","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jid.2021.10.007_bib36","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.2147\/OTT.S117121","article-title":"NRAS-mutant melanoma: current challenges and future prospect","volume":"10","author":"Mu\u00f1oz-Couselo","year":"2017","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.jid.2021.10.007_bib37","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jid.2021.10.007_bib38","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.yexcr.2010.12.019","article-title":"Melanoma cells produce multiple laminin isoforms and strongly migrate on \u03b15 laminin(s) via several integrin receptors","volume":"317","author":"Oikawa","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jid.2021.10.007_bib39","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/jid.2014.503","article-title":"The tryptophan-derived endogenous aryl hydrocarbon receptor ligand 6-Formylindolo[3,2-b]carbazole is a nanomolar UVA photosensitizer in epidermal keratinocytes","volume":"135","author":"Park","year":"2015","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.10.007_bib40","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2159-8290.CD-13-0440","article-title":"Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis","volume":"4","author":"Parmenter","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jid.2021.10.007_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2017.01.029","article-title":"Potential therapeutic targets of epithelial-mesenchymal transition in melanoma","volume":"391","author":"Pearlman","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jid.2021.10.007_bib42","doi-asserted-by":"crossref","first-page":"101594","DOI":"10.1016\/j.redox.2020.101594","article-title":"The sunless tanning agent dihydroxyacetone induces stress response gene expression and signaling in cultured human keratinocytes and reconstructed epidermis","volume":"36","author":"Perer","year":"2020","journal-title":"Redox Biol"},{"key":"10.1016\/j.jid.2021.10.007_bib43","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-05-4671","article-title":"Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity","volume":"66","author":"Petti","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2021.10.007_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3390\/cells10020326","article-title":"Amphiregulin regulates melanocytic senescence","volume":"10","author":"Pommer","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jid.2021.10.007_bib45","doi-asserted-by":"crossref","first-page":"7516","DOI":"10.1158\/0008-5472.CAN-05-3189","article-title":"SPARC represses E-cadherin and induces mesenchymal transition during melanoma development","volume":"66","author":"Robert","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2021.10.007_bib46","doi-asserted-by":"crossref","first-page":"ra30","DOI":"10.1126\/scisignal.2004815","article-title":"BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling","volume":"7","author":"Sanchez-Laorden","year":"2014","journal-title":"Sci Signal"},{"key":"10.1016\/j.jid.2021.10.007_bib47","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/sj.onc.1209379","article-title":"Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma","volume":"25","author":"Sensi","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jid.2021.10.007_bib48","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/0008-5472.CAN-11-0140","article-title":"Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.jid.2021.10.007_bib49","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2217\/fon.09.128","article-title":"CXCL8 and its cognate receptors in melanoma progression and metastasis","volume":"6","author":"Singh","year":"2010","journal-title":"Future Oncol"},{"key":"10.1016\/j.jid.2021.10.007_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.10.007_bib51","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2020.05.009","article-title":"Clinical development of BRAF plus MEK inhibitor combinations","volume":"6","author":"Subbiah","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jid.2021.10.007_bib52","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/s41591-019-0474-7","article-title":"Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients","volume":"25","author":"Sullivan","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2021.10.007_bib53","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/biomedicines9010079","article-title":"Melanoma cell resistance to vemurafenib modifies inter-cellular communication signals","volume":"9","author":"Tabolacci","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jid.2021.10.007_bib54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fmolb.2020.00154","article-title":"Current state of target treatment in BRAF mutated melanoma","volume":"7","author":"Tanda","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jid.2021.10.007_bib55","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/cancers12082154","article-title":"EMT-inducing transcription factors, drivers of melanoma phenotype switching, and resistance to treatment","volume":"12","author":"Tang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jid.2021.10.007_bib56","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fmolb.2020.00172","article-title":"Non-BRAF mutant melanoma: molecular features and therapeutical implications","volume":"7","author":"Vanni","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jid.2021.10.007_bib57","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cell.2019.01.002","article-title":"Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis","volume":"176","author":"Yin","year":"2019","journal-title":"Cell"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2102368X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X2102368X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:48:55Z","timestamp":1762206535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X2102368X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0022202X2102368X"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.10.007","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor\u2012Resistant BRAFV600E\/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}